In NASH experimental models, chymase inhibitor reduced increases in mast cell number in NASH, reducing chymase activity following both direct inhibition by chymase inhibitor and indirect reduction of chymase expression in mast cells [19,20]. The gene discussed is CMA1; the disease is metabolic dysfunction-associated steatohepatitis.